110 results on '"Wainberg, Mark A."'
Search Results
2. Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout
3. M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA
4. M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA
5. A tale of two countries: all‐cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada
6. Monotherapy with either dolutegravir or raltegravir fails to durably suppress HIV viraemia in humanized mice
7. Large cluster outbreaks sustain the HIV epidemic among MSM in Quebec
8. Purification of Zika virus RNA-dependent RNA polymerase and its use to identify small-molecule Zika inhibitors
9. Identification of resveratrol analogs as potent anti‐dengue agents using a cell‐based assay
10. Quality of initial HIV care in Canada: extension of a composite programmatic assessment tool for HIV therapy
11. We need to use the best antiretroviral drugs worldwide to prevent HIV drug resistance
12. The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir
13. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
14. A Resveratrol Analog Termed 3,3′,4,4′,5,5′-Hexahydroxy-trans-Stilbene Is a Potent HIV-1 Inhibitor
15. The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir
16. The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B
17. Natural killer cell education does not affect the magnitude of granzyme B delivery to target cells by antibody-dependent cellular cytotoxicity
18. Dolutegravir inhibits HIV-1 Env evolution in primary human cells
19. The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline
20. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance
21. Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity
22. Has the time come to abandon efavirenz for first-line antiretroviral therapy?
23. Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors
24. Targeting host nucleotide biosynthesis with resveratrol inhibits emtricitabine-resistant HIV-1
25. Defective HIV-1 quasispecies in the form of multiply drug-resistant proviral DNA within cells can be rescued by superinfection with different subtype variants of HIV-1 and by HIV-2 and SIV
26. The preferential selection of K65R in HIV-1 subtype C is attenuated by nucleotide polymorphisms at thymidine analogue mutation sites
27. Development of a fluorescence-based HIV-1 integrase DNA binding assay for identification of novel HIV-1 integrase inhibitors
28. Phylogenetic inferences on HIV-1 transmission: implications for the design of prevention and treatment interventions
29. Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline
30. Harnessing the therapeutic potential of host antiviral restriction factors that target HIV
31. In vitro and structural evaluation of PL-100 as a potential second-generation HIV-1 protease inhibitor
32. The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors
33. Dates of HIV infection can be estimated for seroprevalent patients by coalescent analysis of serial next-generation sequencing data
34. Transmission dynamics of the M184V drug resistance mutation in primary HIV infection
35. Synergy against drug-resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination
36. Development of Antiretroviral Drug Resistance
37. Proof of principle: antiretroviral drugs can prevent sexual transmission of HIV-1
38. Antiviral drug development
39. Subtype Diversity Associated with the Development of HIV-1 Resistance to Integrase Inhibitors
40. AIDS: Drugs that prevent HIV infection
41. Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function
42. HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays
43. Reconsidering the lifetime deferral of blood donation by men who have sex with men
44. Tissue culture drug resistance analysis of a novel HIV-1 protease inhibitor termed PL-100 in non-B HIV-1 subtypes
45. Neither ritonavir nor darunavir affect cell surface expression of tetherin or Vpu-mediated tetherin down-modulation
46. Can the further clinical development of bevirimat be justified?
47. Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine
48. Prevalence of the K65R Resistance Reverse Transcriptase Mutation in Different HIV-1 Subtypes in Israel
49. Criminalizing HIV transmission may be a mistake
50. New findings on blockage of HIV-1 RNase H activity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.